Fondaparinux Sodium Drug Asset Due Diligence Report 2026

This Fondaparinux Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

104

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fondaparinux Sodium can convert its Small molecule drug profile and AT III biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fondaparinux Sodium (query alias: fondaparinux)
Modality / target	Small molecule drug; AT III; AT III activators
Highest global status	Approved
Originator	Organon & Co., Sanofi
Active developers	Viatris Healthcare (Pty) Ltd., Aspen Pharmacare Holdings Ltd., GSK Plc

The MCP disease footprint includes Angina Pectoris, Myocardial Infarction, Acute Coronary Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2300067693	Phase 4	Not yet recruiting	100	VTE rate
NCT06370273	Phase 3	Recruiting	10044	Composite of net clinical benefit comprising clinical VTE event, major bleeding, and cause-specific mortality
NCT07228663	Phase 3	Not yet recruiting	100	Recruitment rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

CHARACTERIZATION AND TREATMENT OF VENOUS THROMBOTIC EVENTS IN PATIENTS WITH VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE

Not Applicable; n=7; evaluation: Positive. Reported fields: -; -; DVT = 3.0 Pts

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Not Applicable; n=811; evaluation: not stated. Reported fields: -; Cumulative Non-Fatal VTE Recurrence at 6 Months (%) = 8.8 percentage of patients ; -

InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)

Phase 4; n=14; evaluation: not stated. Reported fields: -; 30-day Mortality = 2 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fondaparinux Sodium addresses Angina Pectoris, Myocardial Infarction, Acute Coronary Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-09-08	Mylan to Acquire Aspen's Thrombosis Business in Europe	Approved	US$310.4M upfront; US$446.6M milestones; US$757.0M stated total
2013-09-30	Aspen acquires GSK brands and manufacturing site for £700 million.	Approved	US$1,133.6M stated total
2004-04-18	Sanofi-Synthelabo sells Arixtra and Fraxiparine to GSK for 453M euros	Approved	US$545.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for synthesizing fondaparinux sodium”. The milestone feed surfaced a patent-application signal described as “Preparation method of fondaparinux sodium intermediate”. The milestone feed surfaced a patent-application signal described as “Automatic preparation method of fondaparinux sodium pentosaccharide intermediate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO